Results 101 to 110 of about 20,082,992 (152)

Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study. [PDF]

Eur Thyroid J
Changoer P, van Houten P, Ceruti D, van Engen-van Grunsven I, Walraven JEW, Ottevanger PB, Jaeger M, Netea-Maier RT.   +7 more
europepmc   +1 more source

Efficacy of iodine-131-metaiodobenzylguanidine therapy for multiple endocrine neoplasia type 2A-associated metastatic pheochromocytoma: case report and literature review. [PDF]

Endocr J
Suda K, Kimura N, Maeda T, Watanabe S, Nishida S, Shima H, Sugawara T, Uchino S, Ishikawa A, Tanaka T, Furuhashi M, Masumori N, Sakurai A.   +12 more
europepmc   +1 more source

The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC. [PDF]

Cancers (Basel)
Wang JC, Rosas D, Raez LE.
europepmc   +1 more source

Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers. [PDF]

Front Immunol
Park JY, Kwak CH, Chang YC, Kim CH.
europepmc   +1 more source

Cooperation between GDNF/Ret and EphrinA/EphA4 signals for motor axon pathway selection in the limb [PDF]

, 2007
Knott, Laura, Knott, L. F., Knott, L.
core  

Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study. [PDF]

Adv Ther
León-Mateos L, Hochmair MJ, Sánchez-Gastaldo A, Rabeau A, Auliac JB, Morán T, Rieke DT, Iranzo Gomez P, Puri T, Afonso AS, Khanal M, Li XI, Segall G.   +12 more
europepmc   +1 more source

Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients. [PDF]

ACS Pharmacol Transl Sci
Jing R, Miao Y, Daut UN, How SH, Zhang F, Stanslas J.   +5 more
europepmc   +1 more source

Orbital and skull metastases as the initial presentation of lung adenocarcinoma harbouring a MET exon 14 skipping mutation. [PDF]

BMJ Case Rep
Ando E, Hayashi Y, Matsuo Y, Saka H.
europepmc   +1 more source

In Silico Studies of Potent Tyrosine Kinase Inhibitors: Molecular Docking and Pharmacophore Modeling Approaches. [PDF]

Molecules
Mavridis E, Pontiki E, Hadjipavlou-Litina D.   +2 more
europepmc   +1 more source

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study. [PDF]

Curr Oncol
Pierret T, Auliac JB, Ricordel C, Daniel C, Nguyen J, Guisier F, Swalduz A, Curcio H, Desage AL, Bigay-Game L, Huchot E, Falchero L, Doubre H, Bylicki O, Chouaïd C, Greillier L.   +15 more
europepmc   +1 more source